An Open-label Phase 2 Multi-center Study of Enzalutamide and Abiraterone and Biomarkers of Androgen Response and Resistance During Rising PSA: BARRIER-P Trial
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2017
At a glance
- Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms BARRIER-P
- 24 Oct 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2018.
- 24 Oct 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2018.
- 24 Oct 2017 Status changed from recruiting to active, no longer recruiting.